Deloitte Canada Expands Blue J Deal to Bring Proprietary Knowledge and MCP Integration to Legal Work
Published
Deloitte Canada has expanded its agreement with Blue J, a company that works on legal technology. The new deal adds proprietary knowledge to the tools that Deloitte uses, and it includes integration with the Model Context Protocol, known as MCP. MCP is a standard that helps artificial intelligence systems connect to outside data sources and software tools.
The partnership shows how large professional services firms in Canada are investing in artificial intelligence to support their work. By adding proprietary knowledge, the systems can draw on specialized information instead of relying only on general data. This can help professionals find relevant information more quickly when they research tax and legal questions.
MCP integration allows the Blue J tools to work more easily with other systems that a firm already uses. This means that data and software can be connected in a more direct way. The companies have not shared every detail of how the tools will be used across the firm, but the expansion is part of a wider trend toward AI-based tools in the legal and accounting fields.
For Canadian readers, the deal is a sign that AI is becoming a more common part of professional work in the country. As these tools develop, businesses and workers will need to understand both their benefits and their limits.
Sources: Legal IT Insider
More Canada news
- GTA VI Is Here: Where Canadians Can Buy It and Which Consoles Can Run It
- AI Company Anthropic Seeks Gas Lead for Canada with Salary Up to $500,000
- Canadian Startups Warned About Relying on a Single AI Provider
- Bloc Québécois Leader Presents Views on New Environment and Climate Bill
- Newfoundland and Labrador Gives $1.25 Million to Community Food Sharing Association
- Ottawa Plans Study to Strengthen Divorce Act and Address Family Violence
- Canada and U.S. Officials Hold Advisory Committee Meeting for the First Time Since Midterm Elections
- Health Canada Approves New Use for Mounjaro to Lower Heart Risk in Type 2 Diabetes Patients